electroCore (NASDAQ:ECOR – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for electroCore and Anteris Technologies Global, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
electroCore currently has a consensus target price of $18.00, suggesting a potential upside of 57.62%. Anteris Technologies Global has a consensus target price of $16.00, suggesting a potential upside of 109.97%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than electroCore.
Risk and Volatility
Insider & Institutional Ownership
26.7% of electroCore shares are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares electroCore and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -39.96% | -1,956.38% | -81.35% |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
Earnings and Valuation
This table compares electroCore and Anteris Technologies Global”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $36.97 million | 2.79 | -$13.97 million | ($1.66) | -6.88 |
| Anteris Technologies Global | $1.91 million | 388.82 | -$94.14 million | ($1.95) | -3.91 |
electroCore has higher revenue and earnings than Anteris Technologies Global. electroCore is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Summary
Anteris Technologies Global beats electroCore on 8 of the 14 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
